Landmark Trials in the Surgical Management of Mesothelioma.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
13
05
2020
accepted:
31
12
2020
pubmed:
2
2
2021
medline:
15
5
2021
entrez:
1
2
2021
Statut:
ppublish
Résumé
The treatment of mesothelioma has evolved slowly over the last 20 years. While surgery as a standalone treatment has fallen out of favor, the importance of multimodality treatment consisting of combinations of chemotherapy, radiotherapy, and surgery have become more common in operable, fit patients. In this review, we discuss trials in surgery, chemotherapy, and radiation that have shaped contemporary multimodality treatment of this difficult malignancy, and we touch on the new and emerging immunotherapeutic and targeted agents that may change the future treatment of this disease. We also review the multimodality treatment regimens, with particular attention to trimodality therapy and neoadjuvant hemithoracic radiation strategies.
Identifiants
pubmed: 33521898
doi: 10.1245/s10434-021-09589-5
pii: 10.1245/s10434-021-09589-5
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2037-2047Références
Alpert N, van Gerwen M, Taioli E. Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted/banned asbestos use. Transl Lung Cancer Res. 2020;9(Suppl 1):S28–38. https://doi.org/10.21037/tlcr.2019.11.11 .
doi: 10.21037/tlcr.2019.11.11
pubmed: 32206568
pmcid: 7082259
Ruff K. How Canada changed from exporting asbestos to banning asbestos: the challenges that had to be overcome. Int J Environ Res Publ Health. 2017;14(10):1135. https://doi.org/10.3390/ijerph14101135 .
doi: 10.3390/ijerph14101135
Mazurek JM, Syamlal G, Wood JM, Hendricks SA, Weston A. Malignant mesothelioma mortality: United States, 1999–2015. MMWR Morb Mortal Wkly Rep. 2017;66(8):214–8. https://doi.org/10.15585/mmwr.mm6608a3 .
doi: 10.15585/mmwr.mm6608a3
pubmed: 28253224
pmcid: 5657894
Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 2011;89(10):716–24. https://doi.org/10.2471/BLT.11.086678 .
doi: 10.2471/BLT.11.086678
pubmed: 22084509
pmcid: 3209980
Kindler HL, Ismaila N, Armato SG III, Bueno R, Hesdorffer M, Jahan T, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(13):1343–73. https://doi.org/10.1200/JCO.2017.76.6394 .
doi: 10.1200/JCO.2017.76.6394
pubmed: 29346042
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–44. https://doi.org/10.1200/JCO.2003.11.136 .
doi: 10.1200/JCO.2003.11.136
pubmed: 12860938
Opitz I, Scherpereel A, Berghmans T, Psallidas I, Glatzer M, Rigau D, et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2020;58(1):1–24. https://doi.org/10.1093/ejcts/ezaa158 .
doi: 10.1093/ejcts/ezaa158
pubmed: 32448904
Proto C, Signorelli D, Mallone S, Prelaj A, Lo Russo G, Imbimbo M, et al. The prognostic role of TNM staging compared with tumor volume and number of pleural sites in malignant pleural mesothelioma. Clin Lung Cancer. 2019;20(6):e652–60. https://doi.org/10.1016/j.cllc.2019.06.019 .
doi: 10.1016/j.cllc.2019.06.019
pubmed: 31377142
Rice D, Chansky K, Nowak A, Pass H, Kindler H, Shemanski L, et al. Mesothelioma domain of the IASLC staging and prognostic factors committee, advisory boards and participating institutions. The IASLC mesothelioma staging project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma. J Thorac Oncol. 2016;11(12):2100–11. https://doi.org/10.1016/j.jtho.2016.09.121 .
doi: 10.1016/j.jtho.2016.09.121
pubmed: 27687964
Baldini EH, Richards WG, Gill RR, Goodman BM, Winfrey OK, Eisen HM, et al. Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2015;149(5):1374–81. https://doi.org/10.1016/j.jtcvs.2014.10.128 .
doi: 10.1016/j.jtcvs.2014.10.128
pubmed: 25772281
pmcid: 6042876
van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European organisation for research and treatment of cancer lung cancer group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23(28):6881–9. https://doi.org/10.1200/JCO.20005.14.589 .
doi: 10.1200/JCO.20005.14.589
pubmed: 16192580
Bottomley A, Gaafar R, Manegold C, Burgers S, Coens C, Legrand C, et al. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada Intergroup Study. J Clin Oncol. 2006;24(9):1435–42. https://doi.org/10.1200/JCO.2005.03.3027 .
doi: 10.1200/JCO.2005.03.3027
pubmed: 16446322
Arnold DT, Hooper CE, Morley A, White P, Lyburn ID, Searle J, et al. The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial. Br J Cancer. 2015;112(7):1183–9. https://doi.org/10.1038/bjc.2015.77 .
doi: 10.1038/bjc.2015.77
pubmed: 25756395
pmcid: 4385962
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405–14. https://doi.org/10.1016/S0140-6736(15)01238-6 .
doi: 10.1016/S0140-6736(15)01238-6
pubmed: 26719230
Vlahu T, Vigneswaran WT. Pleurectomy and decortication. Ann Transl Med. 2017;5(11):246. https://doi.org/10.21037/atm.2017.04.03 .
doi: 10.21037/atm.2017.04.03
pubmed: 28706914
pmcid: 5497109
Cao C, Yan TD, Bannon PG, McCaughan BC. Summary of prognostic factors and patient selection for extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma. Ann Surg Oncol. 2011;18(10):2973–9. https://doi.org/10.1245/s10434-011-1728-x .
doi: 10.1245/s10434-011-1728-x
pubmed: 21512863
Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135(3):620–6. https://doi.org/10.1016/j.jtcvs.2007.10.054 .
doi: 10.1016/j.jtcvs.2007.10.054
pubmed: 18329481
Lococo F, Torricelli F, Lang-Lazdunski L, Veronesi G, Rena O, Paci M, et al. Survival results in biphasic malignant pleural mesothelioma patients: a multicentric analysis. J Thorac Cardiovasc Surg. 2020;159(4):1584–93. https://doi.org/10.1016/j.jtcvs.2019.08.027 .
doi: 10.1016/j.jtcvs.2019.08.027
pubmed: 31590954
Meyerhoff RR, Yang CF, Speicher PJ, Gulack BC, Hartwig MG, D’Amico TA, et al. Impact of mesothelioma histologic subtype on outcomes in the surveillance, epidemiology, and end results database. J Surg Res. 2015;196(1):23–32. https://doi.org/10.1016/j.jss.2015.01.043 .
doi: 10.1016/j.jss.2015.01.043
pubmed: 25791825
pmcid: 4430361
Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 2014;83(2):240–5. https://doi.org/10.1016/j.lungcan.2013.11.026 .
doi: 10.1016/j.lungcan.2013.11.026
pubmed: 24360321
Burt BM, Cameron RB, Mollberg NM, Kosinski AS, Schipper PH, Shrager JB, et al. Malignant pleural mesothelioma and the society of thoracic surgeons database: an analysis of surgical morbidity and mortality. J Thorac Cardiovasc Surg. 2014;148(1):30–5. https://doi.org/10.1016/j.jtcvs.2014.03.011 .
doi: 10.1016/j.jtcvs.2014.03.011
pubmed: 24726744
Lauk O, Hoda MA, de Perrot M, Friess M, Klikovits T, Klepetko W, et al. Extrapleural pneumonectomy after induction chemotherapy: perioperative outcome in 251 mesothelioma patients from three high-volume institutions. Ann Thorac Surg. 2014;98(5):1748–54. https://doi.org/10.1016/j.athoracsur.2014.05.071 .
doi: 10.1016/j.athoracsur.2014.05.071
pubmed: 25110339
Infante M, Morenghi E, Bottoni E, Zucali P, Rahal D, Morlacchi A, et al. Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2016;50(6):1077–82. https://doi.org/10.1093/ejcts/ezw215 .
doi: 10.1093/ejcts/ezw215
pubmed: 27330149
Sharkey AJ, Tenconi S, Nakas A, Waller DA. The effects of an intentional transition from extrapleural pneumonectomy to extended pleurectomy/decortication. Eur J Cardiothorac Surg. 2016;49(6):1632–41. https://doi.org/10.1093/ejcts/ezv403 .
doi: 10.1093/ejcts/ezv403
pubmed: 26637211
Treasure T, Waller D, Tan C, Entwisle J, O’Brien M, O’Byrne K, et al. The mesothelioma and radical surgery randomized controlled trial: the mars feasibility study. J Thorac Oncol. 2009;4(10):1254–8. https://doi.org/10.1097/JTO.0b013e3181ae26ae .
doi: 10.1097/JTO.0b013e3181ae26ae
pubmed: 19661833
Lim E. Mesothelioma and radical surgery. ClinicalTrials.gov Identifier NCT02040272. https://www.clinicaltrials.gov/ct2/show/NCT02040272
Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, et al. MARS trialists. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12(8):763–72. https://doi.org/10.1016/S1470-2045(11)70149-8 .
doi: 10.1016/S1470-2045(11)70149-8
pubmed: 21723781
pmcid: 3148430
Weder W, Stahel RA, Baas P, Dafni U, de Perrot M, McCaughan BC, et al. The MARS feasibility trial: conclusions not supported by data. Lancet Oncol. 2011;12(12):1093–4. https://doi.org/10.1016/S1470-2045(11)70307-2 .
doi: 10.1016/S1470-2045(11)70307-2
pubmed: 22041539
Utkan G, Yalçin B, Büyükçelik A, Yalçin S. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma: is it safe? J Clin Oncol. 2005;23(3):655. https://doi.org/10.1200/JCO.2005.05.259 .
doi: 10.1200/JCO.2005.05.259
pubmed: 15659523
Weder W, Stahel RA, Bernhard J, Bodis S, Vogt P, Ballabeni P, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol. 2007;18(7):1196–202. https://doi.org/10.1093/annonc/mdm093 .
doi: 10.1093/annonc/mdm093
pubmed: 17429100
Rea F, Marulli G, Bortolotti L, Breda C, Favaretto AG, Loreggian L, et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): feasibility and results. Lung Cancer. 2007;57(1):89–95. https://doi.org/10.1016/j.lungcan.2007.02.004 .
doi: 10.1016/j.lungcan.2007.02.004
pubmed: 17403553
Kapeles M, Gensheimer MF, Mart DA, Sottero TL, Kusano AS, Truong A, et al. Trimodality treatment of malignant pleural mesothelioma: an institutional review. Am J Clin Oncol. 2018;41(1):30–5. https://doi.org/10.1097/COC.0000000000000225 .
doi: 10.1097/COC.0000000000000225
pubmed: 26353120
Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27(18):3007–13. https://doi.org/10.1200/JCO.2008.20.3943 .
doi: 10.1200/JCO.2008.20.3943
pubmed: 19364962
pmcid: 3646305
Van Schil PE, Baas P, Gaafar R, Maat AP, Van de Pol M, Hasan B, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J. 2010;36(6):1362–9. https://doi.org/10.1183/09031936.00039510 .
doi: 10.1183/09031936.00039510
pubmed: 20525721
Bovolato P, Casadio C, Billè A, Ardissone F, Santambrogio L, Ratto GB, et al. Does surgery improve survival of patients with malignant pleural mesothelioma? A multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol. 2014;9(3):390–6. https://doi.org/10.1097/JTO.0000000000000064 .
doi: 10.1097/JTO.0000000000000064
pubmed: 24518090
Sharif S, Zahid I, Routledge T, Scarci M. Extrapleural pneumonectomy or supportive care: treatment of malignant pleural mesothelioma? Interact Cardiovasc Thorac Surg. 2011;12(6):1040–5. https://doi.org/10.1510/icvts.2010.256289 .
doi: 10.1510/icvts.2010.256289
pubmed: 21388982
Sugarbaker DJ, Richards WG, Bueno R. Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients. Ann Surg. 2014;260(4):577–80. https://doi.org/10.1097/SLA.0000000000000903 .
doi: 10.1097/SLA.0000000000000903
pubmed: 25203873
pmcid: 4481127
Cao CQ, Yan TD, Bannon PG, McCaughan BC. A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol. 2010;5(10):1692–703. https://doi.org/10.1097/JTO.0b013e3181ed0489 .
doi: 10.1097/JTO.0b013e3181ed0489
pubmed: 20802345
Bölükbas S, Eberlein M, Schirren J. Prospective study on functional results after lung-sparing radical pleurectomy in the management of malignant pleural mesothelioma. J Thorac Oncol. 2012;7(5):900–5. https://doi.org/10.1097/JTO.0b013e31824de2dc .
doi: 10.1097/JTO.0b013e31824de2dc
pubmed: 22722790
Hasegawa S. Extrapleural pneumonectomy or pleurectomy/decortication for malignant pleural mesothelioma. Gen Thorac Cardiovasc Surg. 2014;62(9):516–21. https://doi.org/10.1007/s11748-014-0389-7 .
doi: 10.1007/s11748-014-0389-7
pubmed: 24639000
pmcid: 4153961
Lang-Lazdunski L, Bille A, Lal R, Cane P, McLean E, Landau D, et al. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. J Thorac Oncol. 2012;7(4):737–43. https://doi.org/10.1097/JTO.0b013e31824ab6c5 .
doi: 10.1097/JTO.0b013e31824ab6c5
pubmed: 22425923
Lim E, Darlison L, Edwards J, Elliott D, Fennell DA, Popat S, et al. MARS 2 trialists. Mesothelioma and radical surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma. BMJ Open. 2020;10(9):e038892. https://doi.org/10.1136/bmjopen-2020-038892 .
doi: 10.1136/bmjopen-2020-038892
pubmed: 32873681
pmcid: 7467531
Senyiğit A, Bayram H, Babayiğit C, Topçu F, Balci AE, Satici O. Comparison of the effectiveness of some pleural sclerosing agents used for control of effusions in malignant pleural mesothelioma: a review of 117 cases. Respiration. 2000;67(6):623–9. https://doi.org/10.1159/000056291 .
doi: 10.1159/000056291
pubmed: 11124644
Horn D, Dequanter D, Lothaire P. Palliative treatment of malignant pleural effusions. Acta Chir Belg. 2010;110(1):32–4. https://doi.org/10.1080/00015458.2010.11680561 .
doi: 10.1080/00015458.2010.11680561
pubmed: 20306906
Thomas R, Piccolo F, Miller D, MacEachern PR, Chee AC, Huseini T, Yarmus L, Bhatnagar R, Lee HJ, Feller-Kopman D, Maskell NA, Tremblay A, Lee YCG. Intrapleural fibrinolysis for the treatment of indwelling pleural catheter-related symptomatic loculations: a multicenter observational study. Chest. 2015;148(3):746–51. https://doi.org/10.1378/chest.14-2401 .
doi: 10.1378/chest.14-2401
pubmed: 25742001
Fysh ET, Tan SK, Read CA, Lee F, McKenzie K, Olsen N, et al. Pleurodesis outcome in malignant pleural mesothelioma. Thorax. 2013;68(6):594–6. https://doi.org/10.1136/thoraxjnl-2012-203043 .
doi: 10.1136/thoraxjnl-2012-203043
pubmed: 23299964
Lumachi F, Mazza F, Ermani M, Chiara GB, Basso SM. Talc pleurodesis as surgical palliation of patients with malignant pleural effusion. Analysis of factors affecting survival. Anticancer Res. 2012;32(11):5071–4.
pubmed: 23155281
Fysh ETH, Bielsa S, Budgeon CA, Read CA, Porcel JM, Maskell NA, et al. Predictors of clinical use of pleurodesis and/or indwelling pleural catheter therapy for malignant pleural effusion. Chest. 2015;147(6):1629–34. https://doi.org/10.1378/chest.14-1701 .
doi: 10.1378/chest.14-1701
pubmed: 25474713
Srivastava V, Dunning J, Au J. Does video-assisted thoracoscopic decortication in advanced malignant mesothelioma improve prognosis? Interact Cardiovasc Thorac Surg. 2009;8(4):454–6. https://doi.org/10.1510/icvts.2008.197160 .
doi: 10.1510/icvts.2008.197160
pubmed: 19136533
Rintoul RC, Ritchie AJ, Edwards JG, Waller DA, Coonar AS, Bennett M, et al. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. 2014;384(9948):1118–27. https://doi.org/10.1016/S0140-6736(14)60418-9 .
doi: 10.1016/S0140-6736(14)60418-9
pubmed: 24942631
Muir KW, Rodger JC. Cardiac tamponade as the initial presentation of malignancy: is it as rare as previously supposed? Postgrad Med J. 1994;70(828):703–7. https://doi.org/10.1136/pgmj.70.828.703 .
doi: 10.1136/pgmj.70.828.703
pubmed: 7831164
pmcid: 2397776
Georghiou GP, Stamler A, Sharoni E, Fichman-Horn S, Berman M, Vidne BA, et al. Video-assisted thoracoscopic pericardial window for diagnosis and management of pericardial effusions. Ann Thorac Surg. 2005;80(2):607–10. https://doi.org/10.1016/j.athoracsur.2005.02.068 .
doi: 10.1016/j.athoracsur.2005.02.068
pubmed: 16039214
McDonald JM, Meyers BF, Guthrie TJ, Battafarano RJ, Cooper JD, Patterson GA. Comparison of open subxiphoid pericardial drainage with percutaneous catheter drainage for symptomatic pericardial effusion. Ann Thorac Surg. 2003;76(3):811–5. https://doi.org/10.1016/s0003-4975(03)00665-9 .
doi: 10.1016/s0003-4975(03)00665-9
pubmed: 12963206
Jama GM, Scarci M, Bowden J, Marciniak SJ. Palliative treatment for symptomatic malignant pericardial effusion†. Interact Cardiovasc Thorac Surg. 2014;19(6):1019–26. https://doi.org/10.1093/icvts/ivu267 .
doi: 10.1093/icvts/ivu267
pubmed: 25142067
Janes SM, Rahman NM, Davies RJ, Lee YC. Catheter-tract metastases associated with chronic indwelling pleural catheters. Chest. 2007;131(4):1232–4. https://doi.org/10.1378/chest.06-2353 .
doi: 10.1378/chest.06-2353
pubmed: 17426232
Schwartz RM, Lieberman-Cribbin W, Wolf A, Flores RM, Taioli E. Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma. BMC Cancer. 2018;18(1):1188. https://doi.org/10.1186/s12885-018-5064-4 .
doi: 10.1186/s12885-018-5064-4
pubmed: 30497433
pmcid: 6267825
de Perrot M, Feld R, Cho BC, Bezjak A, Anraku M, Burkes R, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27(9):1413–8. https://doi.org/10.1200/JCO.2008.17.5604 .
doi: 10.1200/JCO.2008.17.5604
pubmed: 19224855
Stahel RA, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, et al. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol. 2015;16(16):1651–8. https://doi.org/10.1016/S1470-2045(15)00208-9 .
doi: 10.1016/S1470-2045(15)00208-9
pubmed: 26538423
Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, Harrison L, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;122(4):788–95. https://doi.org/10.1067/mtc.2001.116560 .
doi: 10.1067/mtc.2001.116560
pubmed: 11581615
Gomez DR, Hong DS, Allen PK, Welsh JS, Mehran RJ, Tsao AS, et al. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol. 2013;8(2):238–45. https://doi.org/10.1097/JTO.0b013e31827740f0 .
doi: 10.1097/JTO.0b013e31827740f0
pubmed: 23247629
pmcid: 5610569
Thieke C, Nicolay NH, Sterzing F, Hoffmann H, Roeder F, Safi S, et al. Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy. Radiat Oncol. 2015;10:267. https://doi.org/10.1186/s13014-015-0575-5 .
doi: 10.1186/s13014-015-0575-5
pubmed: 26715491
pmcid: 4696301
Bece A, Tin MM, Martin D, Lin R, McLean J, McCaughan B. Hemithoracic radiation therapy after extrapleural pneumonectomy for malignant pleural mesothelioma: toxicity and outcomes at an Australian institution. J Med Imaging Radiat Oncol. 2015;59(3):355–62. https://doi.org/10.1111/1754-9485.12291 .
doi: 10.1111/1754-9485.12291
pubmed: 25753747
Casiraghi M, Maisonneuve P, Brambilla D, Solli P, Galetta D, Petrella F, et al. Induction chemotherapy, extrapleural pneumonectomy and adjuvant radiotherapy for malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2017;52(5):975–81. https://doi.org/10.1093/ejcts/ezx122 .
doi: 10.1093/ejcts/ezx122
pubmed: 28482086
Federico R, Adolfo F, Giuseppe M, Lorenzo S, Martino DT, Anna C, et al. Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma. BMC Cancer. 2013;13:22. https://doi.org/10.1186/1471-2407-13-22 .
doi: 10.1186/1471-2407-13-22
pubmed: 23324131
pmcid: 3722081
Rimner A. Pleurectomy/decortication (Neo) adjuvant chemotherapy and intensity modulated radiation therapy to the pleura in patients with locally advanced malignant pleural mesothelioma. ClinicalTrials.gov identifier NCT00715611. https://clinicaltrials.gov/ct2/show/NCT00715611
Bayman N, Appel W, Ashcroft L, Baldwin DR, Bates A, Darlison L, et al. Prophylactic irradiation of tracts in patients with malignant pleural mesothelioma: an open-label, multicenter, Phase III randomized trial. J Clin Oncol. 2019;37(14):1200–8. https://doi.org/10.1200/JCO.18.01678 .
doi: 10.1200/JCO.18.01678
pubmed: 30920878
Mohiuddin M, Marks J, Marks G. Management of rectal cancer: short- vs. long-course preoperative radiation. Int J Radiat Oncol Biol Phys. 2008;72(3):636–43. https://doi.org/10.1016/j.ijrobp.2008.05.069 .
doi: 10.1016/j.ijrobp.2008.05.069
pubmed: 19014778
Chouliaras K, Senehi R, Ethun CG, Poultsides G, Grignol V, Clarke CN, et al. Role of radiation therapy for retroperitoneal sarcomas: an eight-institution study from the US Sarcoma Collaborative. J Surg Oncol. 2019;120(7):1227–34. https://doi.org/10.1002/jso.25694 .
doi: 10.1002/jso.25694
pubmed: 31486096
pmcid: 6857791
Cho BC, Feld R, Leighl N, Opitz I, Anraku M, Tsao MS, et al. A feasibility study evaluating surgery for mesothelioma after radiation therapy: the “SMART” approach for resectable malignant pleural mesothelioma. J Thorac Oncol. 2014;9(3):397–402. https://doi.org/10.1097/JTO.0000000000000078 .
doi: 10.1097/JTO.0000000000000078
pubmed: 24445595
Chan WH, Sugarbaker DJ, Burt BM. Intraoperative adjuncts for malignant pleural mesothelioma. Transl Lung Cancer Res. 2017;6(3):285–94. https://doi.org/10.21037/tlcr.2017.05.04 .
doi: 10.21037/tlcr.2017.05.04
pubmed: 28713674
pmcid: 5504117
Lopez JA, Krikorian JG, Reich SD, Smyth RD, Lee FH, Issell BF. Clinical pharmacology of intraperitoneal cisplatin. Gynecol Oncol. 1985;20(1):1–9. https://doi.org/10.1016/0090-8258(85)90118-0 .
doi: 10.1016/0090-8258(85)90118-0
pubmed: 4038390
Howell SB, Pfeifle CL, Wung WE, Olshen RA, Lucas WE, Yon JL, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 1982;97(6):845–51. https://doi.org/10.7326/0003-4819-97-6-845 .
doi: 10.7326/0003-4819-97-6-845
pubmed: 6890785
Sugarbaker DJ, Gill RR, Yeap BY, Wolf AS, DaSilva MC, Baldini EH, et al. Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J Thorac Cardiovasc Surg. 2013;145(4):955–63. https://doi.org/10.1016/j.jtcvs.2012.12.037 .
doi: 10.1016/j.jtcvs.2012.12.037
pubmed: 23434448
Friedberg JS. Radical pleurectomy and photodynamic therapy for malignant pleural mesothelioma. Ann Cardiothorac Surg. 2012;1(4):472–80. https://doi.org/10.3978/j.issn.2225-319X.2012.11.14 .
doi: 10.3978/j.issn.2225-319X.2012.11.14
pubmed: 23977539
pmcid: 3741797
Friedberg JS, Culligan MJ, Mick R, Stevenson J, Hahn SM, Sterman D, et al. Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2012;93(5):1658–65. https://doi.org/10.1016/j.athoracsur.2012.02.009 .
doi: 10.1016/j.athoracsur.2012.02.009
pubmed: 22541196
pmcid: 4394024
Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer. 2006;6(7):535–45. https://doi.org/10.1038/nrc1894 .
doi: 10.1038/nrc1894
pubmed: 16794636
pmcid: 2933780
Friedberg JS, Simone CB 2nd, Culligan MJ, Barsky AR, Doucette A, McNulty S, et al. Extended pleurectomy-decortication-based treatment for advanced stage epithelial mesothelioma yielding a median survival of nearly three years. Ann Thorac Surg. 2017;103(3):912–9. https://doi.org/10.1016/j.athoracsur.2016.08.071 .
doi: 10.1016/j.athoracsur.2016.08.071
pubmed: 27825687
Cengel K. Phase II trial of radical pleurectomy with or without intraoperative PDT for malignant pleural mesothelioma. ClinicalTrials.gov identifier: NCT02153229. https://clinicaltrials.gov/ct2/show/NCT02153229
Scagliotti GV, Gaafar R, Nowak AK, Nakano T, van Meerbeeck J, Popat S, et al. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 2019;7(7):569–80. https://doi.org/10.1016/S2213-2600(19)30139-0 .
doi: 10.1016/S2213-2600(19)30139-0
pubmed: 31103412
Maio M, Scherpereel A, Calabrò L, Aerts J, Perez SC, Bearz A, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18(9):1261–73. https://doi.org/10.1016/S1470-2045(17)30446-1 .
doi: 10.1016/S1470-2045(17)30446-1
pubmed: 28729154
pmcid: 28729154
Nowak A, Lesterhuis W, Hughes B, Brown C, Kok P-S, O’Byrne K, et al. DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma—First results. J Clin Oncol. 2018;36:8503. https://doi.org/10.1200/JCO.2018.36.15_suppl.8503 .
doi: 10.1200/JCO.2018.36.15_suppl.8503
Zalcman G, Peters S, Mansfield A, Jahan T, Popat S, Scherpereel A, et al. Checkmate 743: A phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma. J Clin Oncol. 2017;35:TPS8581. https://doi.org/10.1200/JCO.2017.35.15_suppl.TPS8581 .
doi: 10.1200/JCO.2017.35.15_suppl.TPS8581
Bristol-Myers S. A phase III, randomized, open label trial of Nivolumab in combination with ipilimumab versus pemetrexed with cisplatin or carboplatin as first line therapy in unresectable pleural mesothelioma. ClinicalTrials.gov identifier NCT02899299. https://clinicaltrials.gov/ct2/show/NCT02899299
Zalcman G, Peters S, Mansfield AS, Jahan TM, Popat S, Scherpereel A, et al. Checkmate 743: a phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma. J Clin Oncol. 2017;35(15):8581.
doi: 10.1200/JCO.2017.35.15_suppl.TPS8581
Wright K. FDA approves nivolumab plus ipilimumab for previously untreated unresectable malignant pleural mesothelioma. Oncology (Williston Park). 2020;34(11):502–3. https://doi.org/10.46883/ONC.2020.3411.0502 .
doi: 10.46883/ONC.2020.3411.0502
pubmed: 33206991
pmcid: 33206991
Gray SG, Mutti L. Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives. Transl Lung Cancer Res. 2020;9(Suppl 1):S100–19. https://doi.org/10.21037/tlcr.2019.11.23 .
doi: 10.21037/tlcr.2019.11.23
pubmed: 32206576
pmcid: 7082257